Safety and interactions of new antifungals in stem cell transplant recipients

Bibliography

• Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 2010;22(2):138-42
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y. Fungal infections after hematopoietic stem cell transplantation. Int J Hematol 2010;91(4):576-87
   PubMed Web of Science ®Google Scholar
• Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 2009;168(6):313-27
   PubMed Web of Science ®Google Scholar
• Girmenia C, Barosi G, Aversa F, Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 2009;49(8):1226-36
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011;46(5):709-18
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis(2011):52(4):e56-93
   Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Treatment of aspergillosis: clinical practice guidelines of the Infectious diseases Society of America. Clin Infect Dis 2008;46(3):327-60
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious diseases Society of America. Clin Infect Dis(2009):48(5):503-35
   PubMedGoogle Scholar
• Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 2004;33(2):137-52
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010;53(2):95-113
   PubMed Web of Science ®Google Scholar
• Marr KA, Leisenring W, Crippa F, Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103(4):1557-9
   PubMed Web of Science ®Google Scholar
• Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006;27(Suppl 1):12-16
   PubMed Web of Science ®Google Scholar
• Jansen J, Akard LP, Wack MF, Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses 2006;49(5):397-404
   PubMed Web of Science ®Google Scholar
• Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant 2005;36(10):873-7
   PubMed Web of Science ®Google Scholar
• Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997;19(4):343-7
   PubMed Web of Science ®Google Scholar
• Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40(Suppl 6):S414-21
   Google Scholar
• El-Cheikh J, Faucher C, Fürst S, High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007;39(5):301-6
   PubMed Web of Science ®Google Scholar
• Roman E, Osunkwo I, Militano O, Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008;50(2):325-30
   PubMed Web of Science ®Google Scholar
• Krüger WH, Rüssmann B, de Wit M, Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005;113(2):104-8
   PubMed Web of Science ®Google Scholar
• Groll AH, Silling G, Young C, Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010;54(10):4143-9
   PubMed Web of Science ®Google Scholar
• Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009;18(9):1279-95; Erratum in: Expert Opin Investig Drugs. 2009 Dec;18(12):1967
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116(24):5111-18
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011;155(3):318-27
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Rovira M, Maertens J, Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group and the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica 2011;96(2):e9-10; author reply e11
   Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47; Erratum in: N Engl J Med. 2007 Jul 26;357(4):428
   PubMed Web of Science ®Google Scholar
• Scott LJ, Simpson D. Voriconazole : a review of its use in the management of invasive fungal infections. Drugs 2007;67(2):269-98
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45(7):649-63
   PubMed Web of Science ®Google Scholar
• Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35(10):1273-5
   PubMed Web of Science ®Google Scholar
• Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a review. Expert Opin Drug Saf 2003;2(5):475-83
   PubMedGoogle Scholar
• Clancy CJ, Nguyen MH. Long-term voriconazole and skin cancer: is there cause for concern? Curr Infect Dis Rep 2011;13(6):536-43
   PubMedGoogle Scholar
• Cowen EW, Nguyen JC, Miller DD, Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010;62(1):31-7
   PubMed Web of Science ®Google Scholar
• Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17
   PubMed Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF, Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85
   PubMed Web of Science ®Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011;86(8):805-17
   PubMed Web of Science ®Google Scholar
• Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006;63(18):1693-703
   PubMed Web of Science ®Google Scholar
• Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 2. Am J Health Syst Pharm 2006;63(19):1813-20
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis JS II. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 2007;8(8):1155-66
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49(4):1331-6
   PubMed Web of Science ®Google Scholar
• Ascher S, Smith PB, Benjamin DK Jr. Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf 2011;10(2):281-6
   PubMed Web of Science ®Google Scholar
• George J, Reboli AC. Anidulafungin: when and how? The clinician's view. Mycoses 2012;55(1):36-44
   PubMed Web of Science ®Google Scholar
• Trenschel R, Ditschkowski M, Elmaagacli AH, Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 2005;35(6):583-6
   PubMed Web of Science ®Google Scholar
• de Fabritiis P, Spagnoli A, Di Bartolomeo P, Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007;40(3):245-9
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L, Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010;45(7):1227-33
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39(10):1407-16
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R, A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006;38(1):47-51
   PubMed Web of Science ®Google Scholar
• Hashino S, Morita L, Takahata M, Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 2008;87(1):91-7
   PubMed Web of Science ®Google Scholar
• Furrer K, Schaffner A, Vavricka SR, Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002;132(23-24):316-20
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Penzak SR, Polston S, Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002;22(8):961-71
   PubMed Web of Science ®Google Scholar
• Ringdén O, Andström E, Remberger M, Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994;14(Suppl 5):S10-14
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Levêque D, Herbrecht R, The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008;47:779-92
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24-34
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56(6):2806-13
   PubMed Web of Science ®Google Scholar
• Hussaini T, Rüping MJ, Farowski F, Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011;31(2):214-25
   PubMed Web of Science ®Google Scholar
• Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit 2012;34(1):72-6
   PubMed Web of Science ®Google Scholar
• Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26(12):1730-44
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Vfend (voriconazole) package insert. New York, NY: 2008
   Google Scholar
• Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin Pharmacol Ther 2002;71:226-34
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3
   PubMed Web of Science ®Google Scholar
• Tintillier M, Kirch L, Goffin E, Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005;20:664-5
   PubMed Web of Science ®Google Scholar
• Mori T, Aisa Y, Kato J, Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Int J Hematol 2009;90(1):103-7
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Scheetz MH, Pi J, Mehta J. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. Bone Marrow Transplant 2010;45(8):1352-6
   PubMed Web of Science ®Google Scholar
• Busca A. The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. Expert Opin Biol Ther 2011;11(6):687-97
   PubMed Web of Science ®Google Scholar
• Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17
   PubMed Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF, Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85
   PubMed Web of Science ®Google Scholar
• Cornely OA, Helfgott D, Langston A, Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Krishna G, Ma L, Vickery D, Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009;53(11):4749-52
   PubMed Web of Science ®Google Scholar
• Berge M, Chevalier P, Benammar M, Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 2009;31(3):396-9
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Martinho M, Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27(6):825-34
   PubMed Web of Science ®Google Scholar
• Kohl V, Müller C, Cornely OA, Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010;54(1):207-12
   PubMed Web of Science ®Google Scholar
• Swiss Compendium of Drugs. Product information caspofungin. Documed AG; Basel, Switzerland: 2009
   Google Scholar
• Christopeit M, Eikam M, Behre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. Mycoses 2008;51(Suppl 1):19-24
   PubMedGoogle Scholar
• Saner F, Gensicke J, Rath P, Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006;34(6):328-32
   PubMed Web of Science ®Google Scholar
• Fukuoka N, Imataki O, Ohnishi H, Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. Transplant Proc 2010;42(7):2725-30
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007;47(3):305-14
   PubMed Web of Science ®Google Scholar